---
title: 'Clinical Daily Summary: What Happened on October 18, 2026'
headline: Diasome prepares Phase III program after type 1 diabetes trial
description: A study also linked GLP-1 use with lower postsurgical risks, while Novartis
  abandoned a lupus nephritis trial of Fabhalta.
url: https://thebench.bio/news/clinical/2026-10-18
topic: clinical
date: '2026-10-18'
covers:
- '2026-10-18'
date_published: '2026-10-19T00:00:30Z'
date_modified: '2026-10-19T00:00:30Z'
tags:
- Clinical
- Industry
sources: 3
publisher: TheBench.Bio
---

# Clinical Daily Summary: What Happened on October 18, 2026

**Diasome prepares Phase III program after type 1 diabetes trial**

A study also linked GLP-1 use with lower postsurgical risks, while Novartis abandoned a lupus nephritis trial of Fabhalta.

## Today in brief

Diasome is preparing pivotal trials of HDV-insulin after a Phase IIb study found it non-inferior to insulin lispro for A1C reduction and associated with less clinically meaningful hypoglycemia. [1] A medical-record study of more than two million adults linked GLP-1 medication use with lower odds of cardiovascular events and infections after surgery. [2]

## Diasome advances HDV-insulin toward Phase III

Diasome is completing protocol and statistical plans for pivotal trials of HDV-insulin in type 1 diabetes after its 226-person Phase IIb OPTI-2 trial found the treatment non-inferior to insulin lispro for A1C reduction. [1] The trial also linked HDV-insulin to less clinically meaningful hypoglycemia while maintaining glycemic control. [1]

CEO Robert Geho said the company intends to discuss the program with the FDA. [1]

## GLP-1 use linked to lower postsurgical risks

In an analysis of more than two million adults who had surgery, GLP-1 medication use was associated with 11% lower adjusted odds of major cardiovascular events and 8% lower adjusted odds of postoperative infections. [2] The medical-record study found associations, not proof of cause, and did not determine whether stopping treatment before surgery affected outcomes. [2]

## Also worth knowing

- Novartis abandoned a trial of Fabhalta in lupus nephritis. [3]

## The day in numbers

- **226 adults**: OPTI-2 participants randomized to HDV-insulin or insulin lispro [1]
- **More than 2 million adults**: Patients included in the study of GLP-1 use and postsurgical outcomes [2]

## Sources

1. [Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data](<https://www.genengnews.com/topics/translational-medicine/diasomes-hdv-insulin-for-t1d-finalizing-phase-iii-plans-after-promising-data/>), GEN, 2026-10-18
2. [GLP-1 Drugs Linked to Fewer Heart Complications and Infections After Surgery](<https://www.insideprecisionmedicine.com/topics/patient-care/glp-1-drugs-linked-to-fewer-heart-complications-and-infections-after-surgery/>), Inside Precision Medicine, 2026-10-18
3. [Novartis abandons Fabhalta trial in lupus nephritis](<https://pharmaphorum.com/news/novartis-abandons-fabhalta-trial-lupus-nephritis>), pharmaphorum, 2026-10-18

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.genengnews.com/topics/translational-medicine/diasomes-hdv-insulin-for-t1d-finalizing-phase-iii-plans-after-promising-data/>
[2]: <https://www.insideprecisionmedicine.com/topics/patient-care/glp-1-drugs-linked-to-fewer-heart-complications-and-infections-after-surgery/>
[3]: <https://pharmaphorum.com/news/novartis-abandons-fabhalta-trial-lupus-nephritis>